EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NT‐proBNP as a Predictor of Atrial Fibrillation Recurrence After Cryoballoon, Radiofrequency and Pulsed‐Field Ablation

Johannes Bruss iD, Thomas Kueffer iD, Hildegard Tanner, Fabian Noti iD, Andreas Haeberlin iD, Gregor Thalmann, Nikola Asenov Kozhuharov iD, Boldizsar Kovacs iD, Valon Spahiu iD, Claudia Herrera Siklody iD, Tobias Reichlin iD, Laurent Roten iD

Pacing and Clinical Electrophysiology · 2026-09 · 49 (9) · 1364-1373

DOI: 10.1111/pace.70237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pacing and Clinical Electrophysiology, online erschienen am 03.04.2026. Verfasst von Johannes Bruss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Natriuretic Peptide, Brain, Cryosurgery, Peptide Fragments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Natriuretic peptides have shown to predict atrial fibrillation (AF) ablation success using thermal energies. Pulsed‐field ablation (PFA) is a novel AF ablation technology. This study investigates the predictive value of NT‐proBNP and clinical parameters for pulmonary vein isolation (PVI) success using PFA, cryoballoon ablation (CBA), and radiofrequency ablation (RFA).

Methods

We included all patients undergoing primary PVI between May 2019 and December 2023 from our prospective registry, excluding those in randomized trials or without NT‐proBNP measured ≤1 day before the procedure. Follow‐up included 7‐day Holter‐ECGs at 3, 6, and 12 months. The primary endpoint was atrial arrhythmia recurrence between days 90–365. NT‐proBNP was dichotomized using the age‐ and sex‐adjusted 95th percentile in healthy adults.

Results

Among 1,391 patients (median age 67 years; 29% female) undergoing primary PVI with RFA ( n = 302), CBA ( n = 399), or PFA ( n = 690), elevated NT‐proBNP levels were observed in 55%, with no significant differences between ablation modalities. NT‐proBNP correlated with age and left atrial volume and was higher in patients with persistent AF. Overall, 1‐year arrhythmia recurrence rate was 32.1%, without differences between ablation technologies. Elevated NT‐proBNP was associated with recurrence across all subgroups. In multivariate Cox regression, NT‐proBNP and persistent AF were the strongest independent predictors of recurrence. A simplified model including only NT‐proBNP and AF type yielded a concordance index of 0.62.

Conclusions

NT‐proBNP is a robust predictor of atrial arrhythmia recurrence after PVI, independent of the ablation technology, and may support shared, evidence‐based decision‐making with patients regarding ablation success probability.

Trial registration

The Swiss‐AF‐PVI registry is registered with ClinicalTrials.gov (NCT03718364)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationNatriuretic Peptide, BrainCryosurgeryPeptide FragmentsCatheter AblationHumansFemaleRecurrenceMaleAgedBiomarkersPulmonary VeinsPredictive Value of TestsProspective StudiesMiddle AgedRegistriesTreatment Outcome

Stichwörter der Autor:innen

atrial fibrillationcryoballoon ablationoutcomepulmonary vein isolationpulsed‐field ablationradiofrequency ablation

Substanzen

Natriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide FragmentsBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

ORCID-Profile: Johannes Bruss, Thomas Kueffer, Fabian Noti, Andreas Haeberlin, Nikola Asenov Kozhuharov, Boldizsar Kovacs, Valon Spahiu, Claudia Herrera Siklody, Tobias Reichlin, Laurent Roten

Zitieren

APA

Bruss, J., Kueffer, T., Tanner, H., Noti, F., Haeberlin, A., Thalmann, G., Kozhuharov, N. A., Kovacs, B., Spahiu, V., Siklody, C. H., Reichlin, T., & Roten, L. (2026). NT‐proBNP as a Predictor of Atrial Fibrillation Recurrence After Cryoballoon, Radiofrequency and Pulsed‐Field Ablation. Pacing and Clinical Electrophysiology, 49(9), 1364-1373. https://doi.org/10.1111/pace.70237

Vancouver

Bruss J, Kueffer T, Tanner H, Noti F, Haeberlin A, Thalmann G, et al. NT‐proBNP as a Predictor of Atrial Fibrillation Recurrence After Cryoballoon, Radiofrequency and Pulsed‐Field Ablation. Pacing and Clinical Electrophysiology. 2026;49(9):1364-1373. doi:10.1111/pace.70237

BibTeX
@article{Bruss2026,
  author = {Bruss, Johannes and Kueffer, Thomas and Tanner, Hildegard and Noti, Fabian and Haeberlin, Andreas and Thalmann, Gregor and Kozhuharov, Nikola Asenov and Kovacs, Boldizsar and Spahiu, Valon and Siklody, Claudia Herrera and Reichlin, Tobias and Roten, Laurent},
  title = {NT‐proBNP as a Predictor of Atrial Fibrillation Recurrence After Cryoballoon, Radiofrequency and Pulsed‐Field Ablation},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2026},
  volume = {49},
  number = {9},
  pages = {1364--1373},
  doi = {10.1111/pace.70237}
}
Kostenlos starten →